| Literature DB >> 31507642 |
Jennifer Lisa Penner Protudjer1,2,3,4, Roelinde Middelveld1,5, Sven-Erik Dahlén1,5, Staffan Ahlstedt1,5.
Abstract
BACKGROUND: Compared to non-allergic individuals, food allergic individuals have impaired health-related quality of life (HRQL). However, effects of gender and age are unclear. The objective of our study was to describe associations between allergies to common foods and HRQL with consideration to gender and age.Entities:
Keywords: Age; Food allergy; Gender; Health-related quality of life
Year: 2019 PMID: 31507642 PMCID: PMC6727333 DOI: 10.1186/s13223-019-0370-1
Source DB: PubMed Journal: Allergy Asthma Clin Immunol ISSN: 1710-1484 Impact factor: 3.406
Background characteristics of the study population, by gender
| Males (n = 68) | Females (n = 69) | |||||
|---|---|---|---|---|---|---|
| n | Mean | 95% CI | n | Mean | 95% CI | |
| Age (years) | 68 | 24.8 | 12.7; 59.4 | 69 | 33.5 | 13.5; 64.8 |
| Average number of allergies to common foods | 68 | 1.5 | 1; 3 | 69 | 1.5 | 1; 3 |
| Average number of allergies to other foodsa | 68 | 1.6 | 0; 4 | 69 | 1.7 | 0; 4 |
| Time since worst reaction (years) | 65 | 5.3 | 0.4; 15 | 59 | 5.0 | 0.2; 15 |
aIncludes participant-perceived or doctor-diagnosed allergies to other foods
bNon-mutually exclusive categories. Percentages reflect the proportion of respondents with a particular characteristic (type of food allergy, symptom) in relation to the total number of males/females. As such, column percentages exceed 100%
Associations between gender- and age categories and total- and domain specific health-related quality of life (HRQL)
| Overall HRQL | AADR | EI | RAE | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | βa | 95% CI | Mean | βa | 95% CI | Mean | βa | 95% CI | Mean | βa | 95% CI | |
| Gender | ||||||||||||
| Males | 5.00 | Referent | 5.43 | Referent | 4.49 | Referent | 4.34 | Referent | ||||
| Females | 5.23 | 0.33 | − 0.05; 0.69 | 5.63 | 0.27 | − 0.13; 0.63 |
|
|
| 4.58 | 0.30 | − 0.31; 0.91 |
| Age categories (years) | ||||||||||||
| < 18 | 4.96 | Referent | 5.25 | Referent | 4.65 | Referent | 4.45 | Referent | ||||
| 18–39 | 5.34 | 0.17 | − 0.06; 0.39 |
|
|
| 4.84 | 0.01 | − 0.27; 0.28 | 4.46 | 0.10 | − 0.28; 0.48 |
| 40+ |
|
|
| 5.65 | 0.33 | − 0.06; 0.72 |
|
|
| 4.47 | 0.47 | − 0.14; 1.08 |
| Age-specific gender categories | ||||||||||||
| < 18 years | ||||||||||||
| Males | 4.81 | Referent | 5.14 | Referent |
| Referent | 4.46 | Referent | ||||
| Females | 5.29 | 0.52 | − 0.11; 1.15 | 5.49 | 0.41 | − 0.25; 1.07 |
|
|
| 4.42 | − 0.02 | − 1.05; 1.00 |
| 18–39 years | ||||||||||||
| Males | 5.63 | Referent | 6.12 | Referent | 5.11 | Referent | 4.75 | Referent | ||||
| Females | 5.15 | − 0.30 | − 1.07; 0.47 | 5.61 | − 0.37 | − 1.15; 0.41 | 4.68 | − 0.16 | − 1.01; 0.69 | 4.28 | − 0.29 | − 1.65; 1.06 |
| 40+ years | ||||||||||||
| Males | 4.80 | Referent | 5.48 | Referent | 4.15 | Referent |
| Referent | ||||
| Females | 5.27 | 0.47 | − 0.18; 1.13 | 5.76 | 0.44 | − 0.30; 1.18 | 4.52 | 0.21 | − 0.69; 1.11 |
|
|
|
Italic denotes statistically significant results
HRQL is on a scale from 1 to 7, where 1 = best possible HRQL, and 7 = worst possible HRQL
HRQL health-related quality of life, AADR allergen avoidance and dietary restrictions, EI emotional impact, RAE risk of accidental exposure
†p < 0.05
‡p < 0.01
aRepresent mean difference in outcome compared to the reference group. Calculated by linear regression, adjusted for number of food allergies and prescription of an epinephrine autoinjector
Associations between gender-specific age categories and total- and domain specific health-related quality of life (HRQL), in the entire study population
| Overall HRQL | AADR | EI | RAE | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | βa | 95% CI | Mean | βa | 95% CI | Mean | βa | 95% CI | Mean | βa | 95% CI | |
| Males (years) | ||||||||||||
| < 18 | 4.81 | Referent | 5.14 | Referent | 4.35 | Referent | 4.46 | Referent | ||||
| 18–39 |
|
|
|
|
|
| 5.11 | 0.64 | − 0.15; 1.43 | 4.75 | 0.14 | − 1.01; 1.28 |
| 40+ | 4.80 | 0.18 | − 0.58; 0.93 | 5.48 | 0.43 | − 0.36; 1.21 | 4.15 | 0.13 | − 0.77; 1.04 | 3.46 | − 0.66 | − 1.96; 0.64 |
| Females (years) | ||||||||||||
| < 18 | 5.29 | Referent | 5.49 | Referent | 5.31 | Referent | 4.42 | Referent | ||||
| 18–39 | 5.15 | 0.33 | − 0.82; 0.51 | 5.61 | 0.10 | − 0.61; 0.80 | 4.68 | − 0.65 | − 1.45; 0.15 | 4.28 | − 0.19 | − 1.25; 0.86 |
| 40+ | 5.27 | 0.31 | − 0.03; 0.39 | 5.76 | 0.33 | − 0.34; 1.00 | 4.52 | − 0.63 | − 1.40; 0.13 | 4.98 | 0.63 | − 0.37; 1.63 |
Italic denotes statistically significant results
HRQL is on a scale from 1 to 7, where 1 = best possible HRQL, and 7 = worst possible HRQL
HRQL health-related quality of life, AADR allergen avoidance and dietary restrictions, EI emotional impact, RAE risk of accidental exposure
†p < 0.05
‡p < 0.01
aRepresent mean difference in outcome compared to the reference group. Calculated by linear regression, adjusted for number of food allergies and prescription of an epinephrine autoinjector
Associations between gender-specific age categories and total- and domain specific health-related quality of life (HRQL), with consideration to severe symptoms, and time since worst reaction
| Overall HRQL | AADR | EI | RAE | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | βa | 95% CI | Mean | βa | 95% CI | Mean | βa | 95% CI | Mean | βa | 95% CI | |
| Severe symptoms | ||||||||||||
| Males (years) | ||||||||||||
| < 18 | 4.82 | Referent | 5.14 | Referent | 4.39 | Referent | 4.38 | Referent | ||||
| 18–39 | 5.69 | 0.62 | − 0.15; 1.38 |
|
|
| 5.25 | 0.61 | − 0.27; 1.50 | 4.71 | − 0.11 | − 1.40; 1.17 |
| 40+ | 4.94 | 0.24 | − 0.64; 1.12 | 5.43 | 0.36 | − 0.56; 1.27 | 4.65 | 0.40 | − 0.62; 1.43 | 3.55 | − 0.49 | − 1.97; 1.00 |
| Females (years) | ||||||||||||
| < 18 | 5.56 | Referent | 5.75 | Referent | 5.63 | Referent | 4.68 | Referent | ||||
| 18–39 | 5.19 | − 0.34 | − 1.05; 0.38 | 5.64 | − 0.11 | − 0.89; 0.67 |
|
|
| 4.45 | − 0.21 | − 1.39; 0.96 |
| 40+ | 5.39 | − 0.19 | − 0.90; 0.52 | 5.84 | 0.01 | − 0.77; 0.79 | 4.67 | − 0.96 | − 1.83; − 0.09 | 5.28 | 0.66 | − 0.50; 1.82 |
| 0–3 years since worst reaction | ||||||||||||
| Males (years) | ||||||||||||
| < 18 | 5.18 | Referent | 5.52 | Referent | 4.54 | Referent | 5.13 | Referent | ||||
| 18–39 |
|
|
|
|
|
|
|
|
| 5.30 | 0.38 | − 1.25; 2.00 |
| 40+ | 4.98 | − 0.08 | − 1.11; 0.94 | 5.60 | 0.08 | − 1.12; 1.28 | 4.58 | 0.36 | − 0.83; 1.55 | 3.33 | − 1.55 | − 3.24; 0.14 |
| Females (years) | ||||||||||||
| < 18 | 5.62 | Referent | 5.80 | Referent | 5.73 | Referent | 4.70 | Referent | ||||
| 18–39 | 4.54 | − 0.11 | − 0.82; 0.60 | 5.91 | 0.12 | − 0.66; 0.91 | 4.96 | − 0.63 | − 1.43; 0.16 | 4.50 | − 0.02 | − 1.43; 1.40 |
| 40+ | 5.30 | − 0.20 | − 0.92; 0.52 | 5.83 | 0.78 | − 0.72; 0.87 |
|
|
| 4.75 | 0.22 | − 1.21; 1.66 |
| 4+ years since worst reaction | ||||||||||||
| Males (years) | ||||||||||||
| < 18 | 4.23 | Referent | 4.53 | Referent | 4.05 | Referent | 3.40 | Referent | ||||
| 18–39 | 5.36 | 0.89 | − 0.04; 1.82 |
|
|
| 4.85 | 0.35 | − 0.90; 1.61 | 4.50 | 0.43 | − 1.22; 2.08 |
| 40+ | 4.68 | 1.13 | − 0.39; 2.65 |
|
|
| 3.60 | − 0.08 | − 2.12; 1.95 | 4.10 | 1.22 | − 1.47; 3.91 |
| Females (years) | ||||||||||||
| < 18 | 4.89 | Referent | 5.29 | Referent | 4.61 | Referent | 3.86 | Referent | ||||
| 18–39 | 4.94 | − 0.37 | − 1.61; 0.88 | 5.40 | − 0.23 | − 1.61; 1.16 | 4.47 | − 0.63 | − 2.17; 0.90 | 4.11 | − 0.33 | − 2.14; 1.48 |
| 40+ | 5.54 | 0.29 | − 0.91; 1.49 | 6.03 | 0.42 | − 0.94; 1.78 | 4.74 | − 0.32 | − 1.80; 1.16 | 5.59 | 1.39 | − 0.36; 3.13 |
Italic denotes statistically significant results
HRQL is on a scale from 1 to 7, where 1 = best possible HRQL, and 7 = worst possible HRQL
HRQL health-related quality of life, AADR allergen avoidance and dietary restrictions, EI emotional impact, RAE risk of accidental exposure
†p < 0.05
‡p < 0.01
aRepresent mean difference in outcome compared to the reference group. Calculated by linear regression, adjusted for number of food allergies and prescription of an epinephrine autoinjector